RecruitingNCT06588205

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Multicenter, Observational, Retrospective-prospective Study Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

200 participants

Start Date

May 5, 2025

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Summary

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

Eligibility

Min Age: 18 YearsMax Age: 79 Years

Inclusion Criteria6

Diagnosis of nodal and extranodal Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphomas (including low-grade transformed lymphomas; double and triple hit; 11q aberration; not otherwise specified) after 1st January 2019
Presence of one MYC translocation or gain of copies (GCN: \> 3 copies in more than 30% of the nuclei) or amplification evaluated by FISH
Availability of immunohistochemical analysis of CD10, Bcl6, MUM1, Bcl2, Myc, Ki67
Have received curative treatment (e.g. R-CHOP, R DA EPOCH, intensified "Burkitt like" chemotherapies) as first-line therapy
Histological material of adequate size and quality to perform histological review with any additional investigations (immunohistochemistry, FISH and other molecular analysis). A FFPE block must be provided for patient enrollment.
Age between 18 and 79 years

Exclusion Criteria2

Primary lymphomas of the central nervous system, plasmablastic lymphoma, Burkitt's lymphoma, primary mediastinal B lymphoma
Have received palliative treatment

Locations(20)

A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia

Alessandria, Italy

A.O.U. Ospedali Riuniti delle Marche - Clinica di Ematologia

Ancona, Italy

I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

Bari, Italy

ASST Spedali Civili - S.C. Ematologia

Brescia, Italy

I.R.C.C.S. Istituto di Candiolo - FPO

Candiolo, Italy

I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncoematologia

Castelfranco Veneto, Italy

ARNAS Garibaldi - U.O.C. Ematologia

Catania, Italy

A.S.T. Macerata - U.O.S.D Ematologia

Civitanova Marche, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

Florence, Italy

ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

Milan, Italy

Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - S.C. Ematologia

Milan, Italy

A.O.U. di Padova - U.O.C. Ematologia

Padua, Italy

I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1

Padua, Italy

AUSL Modena sede di Sassuolo - UOSD di Oncologia Area Sud

Sassuolo, Italy

U.O.C. Ematologia - A.O.U. Senese

Siena, Italy

A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

Torino, Italy

ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia

Treviso, Italy

A.O. Cardinale "G. Panico" - U.O.C Ematologia e Trapianto Midollo Osseo

Tricase, Italy

A.S.U. Giuliano Isontina - S.C. Ematologia

Trieste, Italy

A.O.U.I. di Verona - Ematologia

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06588205

Related Trials

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT034180384 locations

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716120 locations

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT060263191 location

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347246 locations